Laura Huppert, Breast oncologist at University of California, San Francisco, shared a post on X:
“Grateful for the opportunity to present data from I-SPY2 trial evaluating initial site(s) of metastatic disease after NACT.
- Risk of non-CNS initial distant recurrence increased with increasing RCB status, whereas risk of initial CNS-only initial distant recurrence was consistent across RCB groups
- Higher cT, cN status associated with higher CNS risk
- We need to do more to identify genomic predictors of high CNS risk and incorporate CNS penetrant therapies / screening for those at high risk!”
You can also read: 25 Posts Not to Miss from SABCS 2025